CMC(SH:603122) 第一财经·2025-11-20 12:26Core Viewpoint - The stock price of HeFu China (603122.SH) has surged dramatically, increasing by 291.92% from October 28 to November 20, reaching a historical high of 26.18 yuan per share, despite the company's declining performance and ongoing losses [2][3][7]. Group 1: Stock Performance - HeFu China's stock price experienced a continuous rise, with 12 out of 14 trading days resulting in price increases before the suspension [2][3]. - The stock price rose from approximately 7 yuan on October 28 to 26.18 yuan by November 20, marking a significant increase [5][7]. - The trading volume showed high turnover rates, with several days exceeding 20% and some days over 30% [9][10]. Group 2: Company Financials - HeFu China reported a revenue of 5.49 billion yuan for the first three quarters of the year, a decline of 22.80% year-on-year, and a net loss of approximately 12.39 million yuan, down 146.65% [13]. - The company has faced declining performance for over two years, with projected revenues and net profits for 2024 expected to drop by 14.05% and 41.58%, respectively [13][15]. - The decline in performance is attributed to changes in the macroeconomic environment and price reductions in the medical industry, leading to decreased sales and profit levels [13][15]. Group 3: Market Behavior and Risks - The stock's rapid increase is characterized by speculative trading, primarily driven by retail investors, with significant participation from natural persons and small investors [3][10]. - Despite multiple risk warnings issued by the company, the stock price continued to hit the daily limit up on its resumption of trading [7][11]. - The company acknowledged that its current price-to-earnings ratio of 378.03 is significantly higher than the industry average of 29.37, indicating a potential bubble [7][12].